Stress fuels tumor growth

Previous research also suggests that exposure to stress could speed up the growth of cancer through its impact on gene activity. Researchers from the Dalian Medical University in China in collaboration with colleagues from across the world have located a key mechanism, which chronic stress triggers, that fuels the growth of cancer stem cells that tumors originate from.

More specifically, the researchers have studied this mechanism in mouse models of breast cancer. Their findings showed that the hormone epinephrine, but they also suggest a strategy to counteract the effects of stress mechanisms on cancer cells. “You can kill all the cells you want in a tumor,” notes co-author Keith Kelley, from the University of Illinois at Chicago, “but if the stem cells, or mother cells, are not killed, then the tumor is going to grow and metastasize.

“To see how stress would impact cancer cell growth in the rodents, the researchers put all the mice in small, restrictive enclosures for a week. Then, they split the mice into two groups.
They put one group into large, comfortable enclosures to discontinue the stress; these mice acted as the control group.

The other group stayed in the small enclosures for another 30 days; these mice acted as the experimental group. Following their initial investigation, the scientists saw not only that the stressed mice exhibited changes in behavior that were indicative of depression and anxiety, but also that they had larger cancer tumors than their peers in the control group.

Also, these tumors were growing at a faster rate, and on the whole, the stressed mice also had a greater number of cancer stem cells than the other mice. Still, at this point, it remained unclear exactly how stress contributed to the progression of cancer. According to principal investigator Quentin Liu, from the Institute of Cancer Stem Cell at Dalian Medical University, “The direct signaling network between stress pathways and a cancer-propagating system remains almost completely unknown.”

When they looked into how various physiological factors changed in the mice that had experienced chronic stress, the researchers closed in on a hormone called epinephrine. The stressed mice had much higher levels of this hormone than the mice in the control group. Also, in mice from the experimental group that had received a drug that blocked ADRB2 which is an epinephrine receptor cancer tumors were smaller and the numbers of cancer stem cells were also lower.

When this hormone binds to ADRB2, the interaction boosts levels of lactate dehydrogenase, an enzyme that normally gives muscles an “injection” of energy in a danger situation. This allows the person to either fight the threat or run away from it. A byproduct of this energy boost is the production of an organic compound called lactate. In the case of people with cancer, the harmful cells actually feed on this compound; it allows them to acquire more energy.

This means that if a person has chronic stress, they will have too much lactate dehydrogenase in their system. This, in turn, will activate genes related to cancer growth and allow cancer cells to thrive.
“These data provide a novel pathway that explains how elevated epinephrine caused by chronic stress promotes breast cancer progression by acting directly on cancer stem cells.”

Sure enough, they found that people with high blood levels of epinephrine also had excess lactate dehydrogenase in cancer tumors — which the researchers had access to through breast cancer biopsy samples. People who had higher levels of the stress hormone were likelier to have poorer outcomes following treatment when compared with people with lower epinephrine levels.

The scientists tried to see whether or not they could identify a strategy to block epinephrine’s ill effects on the system. In laboratory tests on breast cancer cell lines, they analyzed the effects of a few Food and Drug Administration (FDA)-approved drugs on lactate dehydrogenase production.
The most promising substance that the investigators settled on was actually vitamin C, which blocked actate dehydrogenase production in laboratory experiments.

When the investigators tested this approach in mouse models, they obtained the same results: Stressed mice they’d injected with vitamin C experienced tumor shrinkage. Vitamin C might be a novel and effective therapeutic agent for targeting cancer in patients undergoing chronic stress,” concludes Liu.